RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Tarsus Pharmaceuticals Stock

Tarsus Pharmaceuticals Liabilities 2024

Tarsus Pharmaceuticals Liabilities

68.5 M USD

Ticker

TARS

ISIN

US87650L1035

In 2024, Tarsus Pharmaceuticals's total liabilities amounted to 68.5 M USD, a 95.72% difference from the 35 M USD total liabilities in the previous year.

Tarsus Pharmaceuticals Aktienanalyse

What does Tarsus Pharmaceuticals do?

Tarsus Pharmaceuticals Inc is an emerging pharmaceutical company specializing in the development of novel therapies for eye diseases. The company was founded in 2016 and is headquartered in Irvine, California. Tarsus focuses on identifying groundbreaking innovative technologies and drugs for the treatment of eye diseases. Tarsus's business model is based on the idea that there are still no effective treatment methods for many eye diseases. For this reason, the company invests in research and development to close this gap and give affected patients new hope. Tarsus's goal is to improve eye health through the development of drugs and therapies. Tarsus is divided into several divisions that focus on different areas of ophthalmology. These include the development of drugs for the treatment of dry eyes, eyelid twitching, age-related macular degeneration, and other eye diseases. Tarsus's first product, TP-03, is a medication for the treatment of conjunctivitis caused by the bacterium Demodex. This condition affects millions of people worldwide and is often difficult to treat. TP-03 is a novel medication specifically targeting Demodex, thus providing an effective treatment option. Another product from Tarsus is TP-04, a medication for the treatment of dry eyes. This condition is one of the most common eye diseases worldwide, affecting millions of people. TP-04 aims to combat the causes of dry eyes and alleviate the symptoms. Tarsus also has a promising pipeline of products in various stages of development. These include medications for age-related macular degeneration, eyelid twitching, and other eye diseases. Tarsus has entered into partnerships with major pharmaceutical companies and research institutions. These partnerships allow the company to bring its products to market faster and reach a larger audience. Overall, Tarsus has the potential to revolutionize ophthalmology and improve the treatment of many eye diseases. The company has a dedicated team of researchers and scientists who are committed to advancing the development of new therapies and medications. Tarsus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Tarsus Pharmaceuticals's Liabilities

Tarsus Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Tarsus Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Tarsus Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Tarsus Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Tarsus Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Tarsus Pharmaceuticals stock

What is the level of liabilities of Tarsus Pharmaceuticals this year?

Tarsus Pharmaceuticals has a debt balance of 68.5 M USD this year.

What were the liabilities of Tarsus Pharmaceuticals compared to the previous year?

The liabilities of Tarsus Pharmaceuticals have increased by 95.72% increased compared to the previous year.

What are the consequences of high debt for investors of Tarsus Pharmaceuticals?

High liabilities can pose a risk for investors of Tarsus Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Tarsus Pharmaceuticals?

Low liabilities mean that Tarsus Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Tarsus Pharmaceuticals affect the company?

An increase in liabilities of Tarsus Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Tarsus Pharmaceuticals affect the company?

A decrease in the liabilities of Tarsus Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Tarsus Pharmaceuticals?

Some factors that can influence the liabilities of Tarsus Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Tarsus Pharmaceuticals so important for investors?

The liabilities of Tarsus Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Tarsus Pharmaceuticals take to modify the liabilities?

To change its liabilities, Tarsus Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Tarsus Pharmaceuticals pay?

Over the past 12 months, Tarsus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Tarsus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Tarsus Pharmaceuticals?

The current dividend yield of Tarsus Pharmaceuticals is .

When does Tarsus Pharmaceuticals pay dividends?

Tarsus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Tarsus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Tarsus Pharmaceuticals located?

Tarsus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tarsus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tarsus Pharmaceuticals from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Tarsus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Tarsus Pharmaceuticals in the year 2023?

In the year 2023, Tarsus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Tarsus Pharmaceuticals pay out the dividend?

The dividends of Tarsus Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Tarsus Pharmaceuticals

Our stock analysis for Tarsus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tarsus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.